Publication:
Role of early circulating tumour cell (CTC) monitoring for prediction of clinical outcome in patients with HER-2 negative metastatic breast cancer receiving first-line treatment with bevacizumab and paclitaxel

Simple item page
dc.contributor.authorÁlvarez López, I.
dc.contributor.authorGonzález, E.
dc.contributor.authorManso, L. M.
dc.contributor.authorAlonso, J. L.
dc.contributor.authorCruz Hernández, J. J.
dc.contributor.authorCarañana Ballerini, V.
dc.contributor.authorGallegos, I.
dc.contributor.authorQuindós Varela, M.
dc.contributor.authorIllaramendi, J. J.
dc.contributor.authorVicente, E.
dc.contributor.authorBallesteros García, A. I.
dc.contributor.authorAyala de la Pena, F.
dc.contributor.authorPerelló, A.
dc.contributor.authorVidal, J.
dc.contributor.authorLlombart Cussac, A.
dc.contributor.departmentMedicina
dc.date.accessioned2024-11-05T11:47:12Z
dc.date.available2024-11-05T11:47:12Z
dc.date.issued2020-05
dc.description© 2020 The Authors. This document is the Published version of a Published Work that appeared in final form in Annals of Oncology. To access the final edited and published work see https://doi.org/10.1016/j.annonc.2020.03.173
dc.description.abstractBackground Circulating tumor cells (CTC) are associated with clinical outcome in metastatic breast cancer (MBC). We explored the ability of early CTC monitoring (after 2 cycles) for predicting clinical benefit (CB), overall response rate (ORR) and outcome in terms of progression-free survival (PFS) and overall survival (OS) in patients (pts) with HER-2 negative MBC receiving first-line treatment with bevacizumab and paclitaxel. Methods Multicenter prospective observational study. Centralized CTC determination was performed at baseline (C0) and after cycle 2 (C2) using CellSearch. A cutoff of 5 CTCs/7.5ml was used to stratify pts into treatment-sensitive (<5 CTCs) and resistant (≥5 CTCs). The optimal CTC level cutoff for predicting CB and PFS was assessed using ROC curves. Results 111 pts were enrolled: median age: 54 years; ECOG 0/1: 50.5/39.6%; triple-negative: 29%; metastatic sites (median): 3; metastases location: liver (62%), bone (58%), lung (40%). The clinical benefit rate (CBR), ORR, and median PFS for the whole cohort were 65%, 41%, and 16.6 months, respectively. With a median follow-up of 17.5 months, the median OS was not achieved. At C0, 43/87 (49%) and 44/87 (50.6%) pts presented with <5 and ≥5 CTCs, respectively. The CTC level after C2 was in 73/85 (86%) and 12/85 (14%) pts <5 and ≥5, respectively. Among pts with CTCs ≥5 at C0, 78% had <5 CTCs after C2. The CTC level after C2 was predictive for CBR (73% vs 59%, p=0,046), ORR (48% vs 17%, p=0.043), and PFS (17 vs. 5 months, p=0.026). Median OS was 13 months in pts with ≥5 CTCs after C2 and it was not achieved in pts with <5 CTCs (p <0.001). A cutoff point of 1 CTC after C2 yielded 65% sensitivity and 61% specificity for prediction of PFS (p=0.021). Pts with 0 CTC achieved a significantly longer PFS vs. those with at least 1 CTC after 2 cycles (22.6 vs. 8.1 months; p=0.005). Grade 3-4 toxicity rate (39%) was not significantly different according to CTCs after 2 cycles (p =0.531). Conclusions CTC monitoring after 2 cycles of first-line bevacizumab-paclitaxel treatment may predict tumor response and clinical outcome in terms of PFS and OS in HER-2 negative MBC.es
dc.formatapplication/pdfes
dc.format.extent1es
dc.identifier.citationAnnals of Oncology, 2020, Vol. 31, N. 2, pp. S29
dc.identifier.doihttps://doi.org/10.1016/j.annonc.2020.03.173
dc.identifier.issnPrint: 0923-7534
dc.identifier.issnElectronic: 1569-8041
dc.identifier.urihttp://hdl.handle.net/10201/145991
dc.languageenges
dc.publisherElsevier
dc.relationRoche Farma S.Aes
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0923753420362529?via%3Dihub
dc.rights.accessRightsinfo:eu-repo/semantics/restrictedAccess
dc.titleRole of early circulating tumour cell (CTC) monitoring for prediction of clinical outcome in patients with HER-2 negative metastatic breast cancer receiving first-line treatment with bevacizumab and paclitaxeles
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
PIIS0923753420362529.pdf
Size:
82.72 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos